According to a pooled analysis of 2,310 HER2-negative breast cancer patients from four prospective neoadjuvant clinical trials (17), fewer grade III tumors, a lower Ki-67 status, and fewer TP53 mutations were found in the HER2-low patients. This evidence concerns the gene ERBB2 and breast cancer.